Cardiovascular health-related quality of life in cancer: A prospective study comparing the ESC HeartQoL and EORTC QLQ-C30 questionnaire
Standard
Cardiovascular health-related quality of life in cancer: A prospective study comparing the ESC HeartQoL and EORTC QLQ-C30 questionnaire. / Anker, Markus S; Potthoff, Sophia K; Lena, Alessia; Porthun, Jan; Hadzibegovic, Sara; Evertz, Ruben; Denecke, Corinna; Fröhlich, Ann-Kathrin; Sonntag, Frederike; Regitz-Zagrosek, Vera; Rosen, Stuart D; Lyon, Alexander R; Lüscher, Thomas F; Spertus, John A; Anker, Stefan D; Karakas, Mahir; Bullinger, Lars; Keller, Ulrich; Landmesser, Ulf; Butler, Javed; von Haehling, Stephan.
in: EUR J HEART FAIL, Jahrgang 25, Nr. 9, 09.2023, S. 1635-1647.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cardiovascular health-related quality of life in cancer: A prospective study comparing the ESC HeartQoL and EORTC QLQ-C30 questionnaire
AU - Anker, Markus S
AU - Potthoff, Sophia K
AU - Lena, Alessia
AU - Porthun, Jan
AU - Hadzibegovic, Sara
AU - Evertz, Ruben
AU - Denecke, Corinna
AU - Fröhlich, Ann-Kathrin
AU - Sonntag, Frederike
AU - Regitz-Zagrosek, Vera
AU - Rosen, Stuart D
AU - Lyon, Alexander R
AU - Lüscher, Thomas F
AU - Spertus, John A
AU - Anker, Stefan D
AU - Karakas, Mahir
AU - Bullinger, Lars
AU - Keller, Ulrich
AU - Landmesser, Ulf
AU - Butler, Javed
AU - von Haehling, Stephan
PY - 2023/9
Y1 - 2023/9
N2 - AIMS: Health-related quality of life (HRQoL) is highly relevant in cancer and often assessed with the EORTC QLQ-C30. Cardiovascular HRQoL in cancer can be measured with the ESC HeartQoL questionnaire. We compared these instruments and examined their prognostic value.METHODS AND RESULTS: Summary scores for EORTC QLQ-C30 (0-100 points) and ESC HeartQoL (0-3 points) questionnaires were prospectively assessed in 290 patients with mostly advanced cancer (stage 3/4: 81%, 1-year mortality: 36%) and 50 healthy controls (similar age and sex). Additionally, physical function and activity assessments were performed. Both questionnaires demonstrated reduced HRQoL in patients with cancer versus controls (EORTC QLQ-C30: 67 ± 20 vs. 91 ± 11, p < 0.001; ESC HeartQoL: 1.8 ± 0.8 vs. 2.7 ± 0.4, p < 0.001). The instruments were strongly correlated with each other (summary scores [r = 0.76], physical [r = 0.81], and emotional subscales [r = 0.75, all p < 0.001]) and independently associated with all-cause mortality (best cut-offs: EORTC QLQ-C30 <82.69: hazard ratio [HR] 2.33, p = 0.004; ESC HeartQoL <1.50: HR 1.85, p = 0.004 - adjusted for sex, age, left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide [NT-proBNP], high-sensitivity troponin T, cancer stage/type), with no differences in the strength of the association by sex (p-interaction > 0.9). Combining both questionnaires identified three risk groups with highest mortality in patients below both cut-offs (vs. patients above both cut-offs: HR 3.60, p < 0.001). Patients with results below both cut-offs, showed higher NT-proBNP and reduced physical function and activity.CONCLUSIONS: The EORTC QLQ-C30 and ESC HeartQoL - assessing cancer and cardiovascular HRQoL - are both associated with increased mortality in cancer patients, with even greater stratification by combing both. Reduced HRQoL scores were associated with elevated cardiovascular biomarkers and decreased functional status.
AB - AIMS: Health-related quality of life (HRQoL) is highly relevant in cancer and often assessed with the EORTC QLQ-C30. Cardiovascular HRQoL in cancer can be measured with the ESC HeartQoL questionnaire. We compared these instruments and examined their prognostic value.METHODS AND RESULTS: Summary scores for EORTC QLQ-C30 (0-100 points) and ESC HeartQoL (0-3 points) questionnaires were prospectively assessed in 290 patients with mostly advanced cancer (stage 3/4: 81%, 1-year mortality: 36%) and 50 healthy controls (similar age and sex). Additionally, physical function and activity assessments were performed. Both questionnaires demonstrated reduced HRQoL in patients with cancer versus controls (EORTC QLQ-C30: 67 ± 20 vs. 91 ± 11, p < 0.001; ESC HeartQoL: 1.8 ± 0.8 vs. 2.7 ± 0.4, p < 0.001). The instruments were strongly correlated with each other (summary scores [r = 0.76], physical [r = 0.81], and emotional subscales [r = 0.75, all p < 0.001]) and independently associated with all-cause mortality (best cut-offs: EORTC QLQ-C30 <82.69: hazard ratio [HR] 2.33, p = 0.004; ESC HeartQoL <1.50: HR 1.85, p = 0.004 - adjusted for sex, age, left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide [NT-proBNP], high-sensitivity troponin T, cancer stage/type), with no differences in the strength of the association by sex (p-interaction > 0.9). Combining both questionnaires identified three risk groups with highest mortality in patients below both cut-offs (vs. patients above both cut-offs: HR 3.60, p < 0.001). Patients with results below both cut-offs, showed higher NT-proBNP and reduced physical function and activity.CONCLUSIONS: The EORTC QLQ-C30 and ESC HeartQoL - assessing cancer and cardiovascular HRQoL - are both associated with increased mortality in cancer patients, with even greater stratification by combing both. Reduced HRQoL scores were associated with elevated cardiovascular biomarkers and decreased functional status.
U2 - 10.1002/ejhf.2951
DO - 10.1002/ejhf.2951
M3 - SCORING: Journal article
C2 - 37369985
VL - 25
SP - 1635
EP - 1647
JO - EUR J HEART FAIL
JF - EUR J HEART FAIL
SN - 1388-9842
IS - 9
ER -
